AstraZeneca has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.

Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as core other operating income.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience.